Announced that Montelukast VersaFilm® has been administered to the first Parkinson’s Disease patients in the Phase 2 clinical trial. IntelGenx Corp. shares T.IGX are trading unchanged at $0.23.
Stocks in play: IntelGenx Corp.
Baystreet.ca - Baystreet - Contributor Content
This article could contain syndicated content. We have not reviewed, approved, or endorsed the content and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here